ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

January 31, 2012

Conditions
Breast CancerCNS Disease
Interventions
DRUG

ZK219477

Given intravenously over approximately 30 minutes once every 3 weeks

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Bayer

INDUSTRY

collaborator

Breast Cancer Research Foundation

OTHER

lead

Nancy Lin, MD

OTHER